CERENOVUS Announces Sustainability Commitment and Showcases New Product and Data Innovations at the Society of NeuroInterventional Surgery 20th Annual Meeting

Cerenovus logo

On-site experience will include a paper-free booth, interactive product demonstrations and a scientific poster session

IRVINE, CA – July 27, 2023 – CERENOVUS, an emerging leader in neurovascular care and part of Johnson & Johnson MedTech,* will share its ongoing commitment to sustainability and showcase its latest innovations in stroke care across its ischemic and hemorrhagic stroke portfolios at the Society of NeuroInterventional Surgery (SNIS) 2023 Annual Meeting and Fellows Course taking place in San Diego, California from July 31 – August 4.

“Stroke shouldn’t be a life sentence, and at CERENOVUS we recognize the importance of addressing unmet clinical needs and the impact this can have on patients and physicians,” said Mark Dickinson, Worldwide President, CERENOVUS. “We’re looking forward to sharing our newest research and latest additions to our ischemic and hemorrhagic portfolios and advancing the field through new sustainability initiatives.”

In support of CERENOVUS’ commitment to protect the environment and reduce waste, the company is pleased to announce that it will utilize electronic instructions for use (e-IFUs) for all new products going forward in regions where allowable. E-IFUs are expected to help reduce the company’s environmental footprint, lower CO2 emissions caused during shipment and facilitate a reduction in healthcare systems’ post-consumer recycling and medical waste disposal. 

Key Poster Presentations
CERENOVUS is proud to support the advancement and understanding of clot and stroke science. Poster presentations include: 

  • E-Poster: “Large Aneurysms in STERLING” by OO Zaidat
  • E-Poster: “What is a Challenging Clot? A Delphi Consensus Statement from the Clot Summit Group” by M. Mirza, J. Ospel and P. Brouwer 
  • E-Poster: “Intracranial Vessel Size Comparison Between European and Chinese Populations for Neurovascular Applications” by M. Mirza, S. Lascalza, J. Wang, K. Kummer, and P. Brouwer

Interactive Experiences in Paper-Free Booth 607
CERENOVUS will host a variety of interactive experiences at its booth, including hands-on demonstrations featuring technologies from its ischemic and hemorrhagic stroke portfolios. The feature for ischemic stroke will be the CEREGLIDE™ 71 Intermediate Catheter – the newest FDA cleared addition to CERENOVUS STROKE SOLUTIONS™, which is a suite of devices designed with compatibility in mind to assist physicians performing life-saving endovascular procedures such as mechanical thrombectomy. On display from the hemorrhagic stroke portfolio will be the CEREPAK™ Family of Coils, which includes a state-of-the-art delivery system designed with ease of use in mind to embolize brain aneurysms. CERENOVUS will also host in-booth talks featuring products from the CERENOVUS portfolio.

Sponsored Programs and Receptions On-Site
CERENOVUS is proud to sponsor multiple programs and receptions on-site during the meeting, building on their commitment to supporting women in neurointervention and continuing education for Fellows. These activities include:

  • Women in Neurointervention Reception & Discussion - This event is taking place on Wednesday, August 2 from 5:30 pm – 7:30 pm PT and will cover physician employment agreements, specifically contract negotiations and industry partnerships. This event is hosted by the Women in Neurointervention Committee. 
  • Fellows Course Hands-On Lab & Reception – This event is taking place on Thursday, August 3 at 5:50 pm PT and will consist of hands-on demonstrations of CERENOVUS innovations.

For more information about CERENOVUS at #SNIS2023, connect with us on Twitter and LinkedIn.

Media Contact: 
Samantha Yakal-Kremski
[email protected]

CERENOVUS, part of Johnson & Johnson MedTech, is an emerging leader in neurovascular care. Our commitment to changing the trajectory of stroke is inspired by our long heritage and dedication to helping physicians protect people from a lifetime of hardship. CERENOVUS offers a broad portfolio of devices used in the endovascular treatment of hemorrhagic and ischemic stroke. For more information, visit cerenovus.com and connect on LinkedIn and Twitter.

About Johnson & Johnson MedTech
At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized. For more information, visit http://www.jnjmedtech.com.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding CERENOVUS STROKE SOLUTIONS, CEREGLIDE™ 71 and CEREPAK™. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of CERENOVUS, Inc., Medical Device Business Services, Inc., any of the other Johnson & Johnson MedTech companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at sec.gov, jnj.com or on request from Johnson & Johnson. Neither Johnson & Johnson MedTech nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

* CERENOVUS, Inc. is a part of Johnson & Johnson MedTech which comprises the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson’s MedTech segment